The lack of significant survival benefits with CTLA-4 inhibitors in HNSCC may reflect the complex immune microenvironment of these tumors, necessitating further exploration of biomarkers and novel combination strategies. This evidence concerns the gene CTLA4 and head and neck squamous cell carcinoma.